<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287248</url>
  </required_header>
  <id_info>
    <org_study_id>AMYLOID001</org_study_id>
    <nct_id>NCT00287248</nct_id>
  </id_info>
  <brief_title>Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain</brief_title>
  <official_title>Evaluation of [123I] IMPY and SPECT as a Marker of Beta-amyloid Protein Deposition in the Brain of Healthy Subjects and Patients With Alzheimer Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Molecular NeuroImaging</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Neurodegenerative Disorders</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is designed to obtain efficacy and safety information for 123-I IMPY as an
      imaging biomarker for Alzheimer's disease (AD). The distribution of this agent will be
      measured by obtaining single photon emission computed tomography (SPECT) images of the brain
      serially over time to determine the relative localization of the radiopharmaceutical in
      regions of the cortex relative to background regions and develop an optimal technique of
      radiotracer administration (bolus or bolus with constant infusion). The researchers will then
      evaluate the utility of 123-I IMPY and SPECT in AD patients as an early diagnostic tool and
      subsequently serial evaluations of AD patients will be performed to determine if this
      technique may be useful as a tool for evaluation of progressive brain β-amyloid deposition in
      AD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All study procedures will be conducted at the Institute for Neurodegenerative Disorders (IND)
      and Molecular NeuroImanging (MNI) in New Haven, CT. Approximately 25 patients with mild to
      moderate Alzheimer's disease (AD) and 20 healthy controls will be recruited to participate in
      this study. AD patients will be eligible to participate if they have a diagnosis of AD of
      less than 3 years duration. Healthy controls will be examined to ensure that there is no
      evidence of neurodegenerative changes including cognitive decline. All subjects will undergo
      written informed consent and a screening evaluation including baseline clinical laboratory
      testing, a baseline physical and neurological evaluation and baseline cognitive evaluations.
      Subjects will be asked to undergo either a bolus injection or bolus injection followed by
      continuous infusion of 123-I IMPY. Following injection, subjects will undergo serial SPECT
      imaging scans and serial venous plasma sampling for measurement of 123-I IMPY in plasma (both
      protein bound and free) over a 3.5 - 8 hour period. The imaging analyses will be performed by
      an image-processing specialist who will remain masked to the procedures employed with each
      imaging acquisition. The primary imaging outcome measure will be the brain regional
      distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, 123-I
      IMPY.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Does 123-I IMPY demonstrate qualitatively increased radiotracer uptake in cortical regions consistent with β-amyloid deposition in AD patients relative to controls</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Can 123-I IMPY and SPECT provide a quantitative and reproducible measure of amyloid deposition</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Assess [123I] IMPY &amp; SPECT Imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To assess [123I] IMPY &amp; SPECT Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[123I] IMPY &amp; SPECT Imaging</intervention_name>
    <description>Subjects will be injected with 7mCi of [123I]IMPY, followed by SPECT imaging</description>
    <arm_group_label>Assess [123I] IMPY &amp; SPECT Imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The participant is 50 years or older.

          -  Written informed consent is obtained.

          -  Participants have a clinical diagnosis of Alzheimer's disease based on National
             Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease
             and Related Disorders Association (NINCDS/ADRA) criteria.

          -  Mini-Mental Status Exam score &gt; 16 and &lt; 25.

          -  Patients have a diagnosis of probable AD for &lt; 3 years prior to screening.

        Exclusion Criteria:

          -  The subject has signs or symptoms of another neurodegenerative disease including
             Parkinson's disease, diffuse Lewy body dementia, or history of significant
             cerebrovascular disease.

          -  Subjects with an iodine allergy.

          -  The subject has a clinically significant clinical laboratory value and/or medical or
             psychiatric illness.

          -  The subject has any disorder that may interfere with drug absorption distribution,
             metabolism, or excretion (including gastrointestinal surgery).

          -  The subject has evidence of clinically significant thyroid disease, gastrointestinal,
             cardiovascular, hepatic, renal, hematologic, neoplastic, endocrine, neurologic,
             immunodeficiency, pulmonary, or other medical or psychiatric disorder.

          -  The subject has received an investigational drug within 60 days before the screening
             visit.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danna L Jennings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 2001 Mar;7(3):369-72.</citation>
    <PMID>11231639</PMID>
  </reference>
  <reference>
    <citation>Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. Epub 2003 Feb 3. Erratum in: Proc Natl Acad Sci U S A. 2004 Aug 3;101(3):11526.</citation>
    <PMID>12566568</PMID>
  </reference>
  <reference>
    <citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000 Aug;6(8):916-9.</citation>
    <PMID>10932230</PMID>
  </reference>
  <reference>
    <citation>Cai L, Chin FT, Pike VW, Toyama H, Liow JS, Zoghbi SS, Modell K, Briard E, Shetty HU, Sinclair K, Donohue S, Tipre D, Kung MP, Dagostin C, Widdowson DA, Green M, Gao W, Herman MM, Ichise M, Innis RB. Synthesis and evaluation of two 18F-labeled 6-iodo-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer's disease. J Med Chem. 2004 Apr 22;47(9):2208-18.</citation>
    <PMID>15084119</PMID>
  </reference>
  <reference>
    <citation>Cummings JL. Alzheimer's disease. N Engl J Med. 2004 Jul 1;351(1):56-67. Review.</citation>
    <PMID>15229308</PMID>
  </reference>
  <reference>
    <citation>DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5. Epub 2001 Jul 3.</citation>
    <PMID>11438712</PMID>
  </reference>
  <reference>
    <citation>DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002 Mar 22;295(5563):2264-7.</citation>
    <PMID>11910111</PMID>
  </reference>
  <reference>
    <citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002 May;5(5):452-7.</citation>
    <PMID>11941374</PMID>
  </reference>
  <reference>
    <citation>Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004 Jan;14(1):11-20.</citation>
    <PMID>14997933</PMID>
  </reference>
  <reference>
    <citation>Folstein MF, Folstein SE, McHugh PR. Cognitive defect in medical illness. Ann Intern Med. 1977 Jun;86(6):827-8.</citation>
    <PMID>869368</PMID>
  </reference>
  <reference>
    <citation>Foster DM. Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. Adv Exp Med Biol. 1998;445:59-78.</citation>
    <PMID>9781382</PMID>
  </reference>
  <reference>
    <citation>Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005 May 10;64(9):1563-72.</citation>
    <PMID>15883317</PMID>
  </reference>
  <reference>
    <citation>Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ; National Institute on Aging Biological Markers Working Group. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging. 2003 Jul-Aug;24(4):521-36. Review.</citation>
    <PMID>12714109</PMID>
  </reference>
  <reference>
    <citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005 May 10;64(9):1553-62.</citation>
    <PMID>15883316</PMID>
  </reference>
  <reference>
    <citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002 Jul 19;297(5580):353-6. Review. Erratum in: Science 2002 Sep 27;297(5590):2209.</citation>
    <PMID>12130773</PMID>
  </reference>
  <reference>
    <citation>Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 2002 Nov;8(11):1270-5. Epub 2002 Oct 15.</citation>
    <PMID>12379846</PMID>
  </reference>
  <reference>
    <citation>Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003 May 22;38(4):547-54.</citation>
    <PMID>12765607</PMID>
  </reference>
  <reference>
    <citation>Holtzman DM. Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J Mol Neurosci. 2001 Oct;17(2):147-55. Review.</citation>
    <PMID>11816788</PMID>
  </reference>
  <reference>
    <citation>Jost BC, Grossberg GT. The natural history of Alzheimer's disease: a brain bank study. J Am Geriatr Soc. 1995 Nov;43(11):1248-55.</citation>
    <PMID>7594159</PMID>
  </reference>
  <reference>
    <citation>Kung HF, Kung MP, Zhuang ZP, Hou C, Lee CW, Plössl K, Zhuang B, Skovronsky DM, Lee VM, Trojanowski JQ. Iodinated tracers for imaging amyloid plaques in the brain. Mol Imaging Biol. 2003 Nov-Dec;5(6):418-26.</citation>
    <PMID>14667496</PMID>
  </reference>
  <reference>
    <citation>Kung MP, Hou C, Zhuang ZP, Cross AJ, Maier DL, Kung HF. Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1136-45. Epub 2004 Mar 9.</citation>
    <PMID>15007564</PMID>
  </reference>
  <reference>
    <citation>Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, Lee VM, Kung HF. IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res. 2002 Nov 29;956(2):202-10.</citation>
    <PMID>12445687</PMID>
  </reference>
  <reference>
    <citation>Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res. 2004 Oct 29;1025(1-2):98-105. Erratum in: Brain Res. 2005 Jan 21;1031(2):302.</citation>
    <PMID>15464749</PMID>
  </reference>
  <reference>
    <citation>Kung MP, Zhuang ZP, Hou C, Kung HF. Development and evaluation of iodinated tracers targeting amyloid plaques for SPECT imaging. J Mol Neurosci. 2004;24(1):49-53. Review.</citation>
    <PMID>15314249</PMID>
  </reference>
  <reference>
    <citation>Kung MP, Zhuang ZP, Hou C, Jin LW, Kung HF. Characterization of radioiodinated ligand binding to amyloid beta plaques. J Mol Neurosci. 2003;20(3):249-54.</citation>
    <PMID>14501004</PMID>
  </reference>
  <reference>
    <citation>Loevinger R, Budinger T, Watson E: MIRD Primer for Absorbed Dose Calculations, Society of Nuclear Medicine, 1988.</citation>
  </reference>
  <reference>
    <citation>Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005 Jan 11;64(1):129-31.</citation>
    <PMID>15642916</PMID>
  </reference>
  <reference>
    <citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939-44.</citation>
    <PMID>6610841</PMID>
  </reference>
  <reference>
    <citation>Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13-21.</citation>
    <PMID>9236948</PMID>
  </reference>
  <reference>
    <citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003 Apr;9(4):448-52. Epub 2003 Mar 17.</citation>
    <PMID>12640446</PMID>
  </reference>
  <reference>
    <citation>Okamura N. [In vivo imaging of amyloid plaques in the brain]. Nihon Ronen Igakkai Zasshi. 2004 Mar;41(2):175-8. Japanese.</citation>
    <PMID>15148750</PMID>
  </reference>
  <reference>
    <citation>Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003 Jul 8;61(1):46-54.</citation>
    <PMID>12847155</PMID>
  </reference>
  <reference>
    <citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002 Nov 15;298(5597):1379.</citation>
    <PMID>12434053</PMID>
  </reference>
  <reference>
    <citation>Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975 Mar;31(1):103-15.</citation>
    <PMID>1100130</PMID>
  </reference>
  <reference>
    <citation>Price DL, Sisodia SS, Borchelt DR. Alzheimer disease--when and why? Nat Genet. 1998 Aug;19(4):314-6.</citation>
    <PMID>9697686</PMID>
  </reference>
  <reference>
    <citation>Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005 Jan 19;25(3):629-36.</citation>
    <PMID>15659599</PMID>
  </reference>
  <reference>
    <citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 Nov;141(11):1356-64.</citation>
    <PMID>6496779</PMID>
  </reference>
  <reference>
    <citation>Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980 May;7(5):486-8.</citation>
    <PMID>7396427</PMID>
  </reference>
  <reference>
    <citation>Schenk DB, Rydel RE, May P, Little S, Panetta J, Lieberburg I, Sinha S. Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease. J Med Chem. 1995 Oct 13;38(21):4141-54. Review.</citation>
    <PMID>7473539</PMID>
  </reference>
  <reference>
    <citation>Schenk DB, Seubert P, Lieberburg I, Wallace J. beta-peptide immunization: a possible new treatment for Alzheimer disease. Arch Neurol. 2000 Jul;57(7):934-6. Review.</citation>
    <PMID>10891974</PMID>
  </reference>
  <reference>
    <citation>Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. J Nucl Med. 1996 Jan;37(1):11-5.</citation>
    <PMID>8543979</PMID>
  </reference>
  <reference>
    <citation>Seibyl JP, Woods SW, Zoghbi SS, Baldwin RM, Dey HM, Goddard AW, Zea-Ponce Y, Zubal G, Germine M, Smith EO, et al. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM. J Nucl Med. 1992 Nov;33(11):1964-71.</citation>
    <PMID>1432157</PMID>
  </reference>
  <reference>
    <citation>Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005 Jun;46(6):1023-7.</citation>
    <PMID>15937315</PMID>
  </reference>
  <reference>
    <citation>Zhuang ZP, Kung MP, Wilson A, Lee CW, Plössl K, Hou C, Holtzman DM, Kung HF. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. J Med Chem. 2003 Jan 16;46(2):237-43.</citation>
    <PMID>12519062</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2006</study_first_submitted>
  <study_first_submitted_qc>February 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2006</study_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Neurodegenerative Disorders</investigator_affiliation>
    <investigator_full_name>Danna Jennings, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>Alzheimer disease</keyword>
  <keyword>Alzheimer disease (AD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2,3-dihydro-1H-imidazo(1,2-b)pyrazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

